How to manage high gastrin levels?

From the Guidelines

Managing high gastrin levels requires identifying and treating the underlying cause, with the most recent and highest quality study suggesting that for hypergastrinemia caused by proton pump inhibitor (PPI) use, gradually tapering and discontinuing the medication under medical supervision is recommended 1.

Key Considerations

• If caused by Zollinger-Ellison syndrome, high-dose PPIs like omeprazole (60-120 mg daily) or pantoprazole (80-240 mg daily) are the primary treatment to control acid hypersecretion.
• For gastrinomas, surgical resection is preferred when possible.
• Type 1 gastric neuroendocrine tumors may require endoscopic removal and monitoring.
• Patients with pernicious anemia should receive vitamin B12 supplementation (1000 mcg intramuscularly monthly or 1000-2000 mcg orally daily).
• H. pylori infection should be treated with standard triple or quadruple therapy regimens.

Monitoring and Surveillance

• Regular monitoring of gastrin levels and endoscopic surveillance are important for all patients with hypergastrinemia.
• Dietary modifications like avoiding high-protein meals that stimulate gastrin secretion may provide modest benefits.
• Gastrin levels are elevated when stomach acid is reduced because acid normally provides negative feedback to gastrin-producing G cells, so addressing the acid-gastrin feedback loop is central to management 1.

Treatment Approach

• The approach to treatment should be individualized based on the underlying cause of hypergastrinemia and the presence of any underlying conditions such as gastrinomas or type 1 gastric neuroendocrine tumors.
• The most recent study suggests that endoscopists may consider resecting small type I gNETs (<1 cm) and lesions measuring 1–2 cm should be endoscopically resected by an endoscopist with experience in resection of gastric lesions 1.

From the FDA Drug Label

In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.

To manage high gastrin levels, discontinuation of omeprazole therapy may be considered, as gastrin values typically return to pretreatment levels within 1 to 2 weeks after stopping the medication 2. It is essential to monitor serum gastrin levels and adjust treatment accordingly. If high gastrin levels persist, alternative treatments may be necessary to manage the underlying condition. Temporarily stopping omeprazole treatment at least 14 days before assessing gastrin levels may also be recommended to allow gastrin levels to return to baseline 2.

From the Research

Managing High Gastrin Levels

To manage high gastrin levels, particularly in the context of Zollinger-Ellison syndrome (ZES), several approaches can be considered:

• Proton Pump Inhibitors (PPIs): PPIs, such as omeprazole and lansoprazole, are effective in controlling gastric acid hypersecretion 3, 4, 5, 6. They can be administered orally or intravenously, with the latter being useful in acute care settings or when oral administration is not feasible 5.
• Surgical Intervention: For patients with localized gastrinomas, surgical tumorectomy may be considered with curative intent 4. However, in many cases, complete surgical removal may not be possible, necessitating long-term medical therapy.
• Somatostatin Analogs: These have been shown to be effective in controlling tumor progression in patients with ZES, particularly in those with well-differentiated, low-grade tumors 7. Somatostatin analogs can be used as anti-proliferative agents in patients not amenable to surgical cure.
• Diagnostic Tests: For the diagnosis of ZES, tests such as fasting serum gastrin concentration, gastric secretion analysis, and secretin stimulation of serum gastrin are useful 3, 4. Endoscopic ultrasound can also be helpful in diagnosing and locally staging the primary tumor, especially in patients with multiple endocrine neoplasia type 1 4.

Treatment Goals

The primary goals in managing ZES include:

• Controlling gastric acid hypersecretion to prevent complications such as peptic ulcers and diarrhea.
• Controlling tumor growth, particularly in cases where surgical cure is not possible.
• Managing symptoms and improving quality of life for patients with ZES.

Considerations

• Differential Diagnosis: It's crucial to rule out other causes of hypergastrinemia to make an accurate diagnosis of ZES 4.
• Multidisciplinary Approach: The management of ZES often requires a multidisciplinary approach, involving gastroenterologists, surgeons, endocrinologists, and other specialists 4.
• Monitoring and Follow-Up: Regular monitoring of gastric acid secretion, tumor progression, and patient symptoms is essential for adjusting treatment plans as needed 3, 7, 5.